ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP

The impact of pharmacogenetics on predicting survival in diffuse large B-cell lymphoma (DLBCL) remains unclear. We tested 337 DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 9 single nucleotide polymorphisms from 6 genes (CD20, FCGR2A, NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Duo, Wu, Nan, Sun, Haiming, Dong, Mei, Guo, Tianzhu, Chi, Peng, Li, Guofu, Sun, Donglin, Jin, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601652/
https://www.ncbi.nlm.nih.gov/pubmed/28938556
http://dx.doi.org/10.18632/oncotarget.16869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601652/
https://www.ncbi.nlm.nih.gov/pubmed/28938556
http://dx.doi.org/10.18632/oncotarget.16869

Ejemplares similares